Compare FLS & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLS | NUVL |
|---|---|---|
| Founded | 1790 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Fluid Controls | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8B | 7.1B |
| IPO Year | N/A | 2021 |
| Metric | FLS | NUVL |
|---|---|---|
| Price | $71.69 | $104.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 14 |
| Target Price | $75.50 | ★ $134.29 |
| AVG Volume (30 Days) | ★ 1.5M | 828.0K |
| Earning Date | 10-28-2025 | 10-30-2025 |
| Dividend Yield | ★ 1.17% | N/A |
| EPS Growth | ★ 69.42 | N/A |
| EPS | ★ 3.44 | N/A |
| Revenue | ★ $4,687,417,000.00 | N/A |
| Revenue This Year | $5.80 | N/A |
| Revenue Next Year | $4.04 | N/A |
| P/E Ratio | $20.80 | ★ N/A |
| Revenue Growth | ★ 3.19 | N/A |
| 52 Week Low | $37.34 | $55.54 |
| 52 Week High | $74.63 | $112.88 |
| Indicator | FLS | NUVL |
|---|---|---|
| Relative Strength Index (RSI) | 59.81 | 51.87 |
| Support Level | $71.10 | $103.52 |
| Resistance Level | $74.63 | $107.99 |
| Average True Range (ATR) | 1.78 | 3.18 |
| MACD | -0.30 | -0.93 |
| Stochastic Oscillator | 51.01 | 10.43 |
Flowserve Corp is a manufacturer and aftermarket service provider of comprehensive flow control systems. It develops precision-engineered flow control equipment to monitor movement and protect customers' materials and processes. It offers an extensive range of pumps, valves, seals, and services for several industries, including oil and gas, chemical, power generation, and water management. It has three business segments: FPD for custom engineered pumps, pre-configured industrial pumps, pump systems, mechanical seals, auxiliary systems and replacement parts and related services; and FCD for engineered-to-order and configured-to-order isolation values, control valves, valve automation products and related equipment and Eliminations and All Other.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.